Drugs / LP-PRP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable1 trial | ||||||
| — | NCT06040203 | Mar 2023 → Mar 2027 expected | epicondylitis | Rizzoli Orthopaedic Institute | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT06020794 Comparator | Feb 2021 → Aug 2022 | chondromalacia patellae | Kayseri City Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LP-PRP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06040203 ↗ |
| Known as | leukocyte poor platelet rich plasma | “Injection of autologous leukocyte poor platelet rich plasma (LP-PRP)” NCT06040203 ↗ |
| Modality | Other / unclassified | “Biological: LP-PRP” NCT06020794 ↗ |
| Route | Other | “2 doses of suprapatellar bursa were injected with 2 doses of 3 cc LP-PRP” NCT06020794 ↗ |